MER W8020

Drug Profile

MER W8020

Latest Information Update: 02 Sep 1998

Price : $50

At a glance

  • Originator Mercian
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Depsipeptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pain; Rheumatoid arthritis

Most Recent Events

  • 02 Sep 1998 No-Development-Reported for Rheumatoid arthritis in Japan (Intraperitoneal)
  • 02 Sep 1998 No-Development-Reported for Pain in Japan (Intraperitoneal)
  • 13 Sep 1996 Preclinical development for Rheumatoid arthritis in Japan (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top